Sanofi Consumer

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0UOS01011
  • NSEID: SANOFICONR
  • BSEID: 544250
INR
4,767.70
7 (0.15%)
BSENSE

May 08

BSE+NSE Vol: 5.23 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Alivus Life
Strides Pharma
Sanofi Consumer
Caplin Point Lab
Viyash Scientifi
Marksans Pharma
Alembic Pharma
P & G Health Ltd
Jubilant Pharmo
Concord Biotech
Corona Remedies

Why is Sanofi Consumer Healthcare India Ltd ?

1
High Management Efficiency with a high ROE of 76.98%
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 10.10% and Operating profit at 5.70% over the last 5 years
4
The company has declared Positive results for the last 3 consecutive quarters
  • NET SALES(Latest six months) At Rs 480.20 cr has Grown at 39.88%
  • PAT(Q) Highest at Rs 67.80 cr.
  • EPS(Q) Highest at Rs 29.48
5
With ROE of 98.4, it has a Very Expensive valuation with a 42.7 Price to Book Value
  • Over the past year, while the stock has generated a return of -3.74%, its profits have fallen by 0% ; the PEG ratio of the company is 2.6
6
High Institutional Holdings at 20.33%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -3.74% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Sanofi Consumer should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Sanofi Consumer for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Sanofi Consumer
-3.85%
-0.11
35.00%
Sensex
-3.74%
-0.28
13.48%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
10.10%
EBIT Growth (5y)
5.70%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
2.77
Tax Ratio
25.07%
Dividend Payout Ratio
69.89%
Pledged Shares
0
Institutional Holding
20.33%
ROCE (avg)
-178.66%
ROE (avg)
76.98%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
43
Industry P/E
35
Price to Book Value
42.73
EV to EBIT
33.63
EV to EBITDA
32.33
EV to Capital Employed
157.78
EV to Sales
11.54
PEG Ratio
2.63
Dividend Yield
NA
ROCE (Latest)
368.27%
ROE (Latest)
98.37%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company
NET SALES(Latest six months)

At Rs 480.20 cr has Grown at 39.88%

PAT(Q)

Highest at Rs 67.80 cr.

EPS(Q)

Highest at Rs 29.48

0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...

Here's what is working for Sanofi Consumer

Profit After Tax (PAT) - Quarterly
Highest at Rs 67.80 cr. and Grown
each quarter in the last five quarters
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Latest six months
At Rs 480.20 cr has Grown at 39.88%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 29.48
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Sanofi Consumer

Non Operating Income - Quarterly
Highest at Rs 5.60 cr
in the last five quarters
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating Income